Incidence of venous thrombosis after peg-asparaginase in adolescent and young adults with acute lymphoblastic leukemia.
acute lymphoblastic leukemia
adolescent young adult
peg-asparaginase
risk factors
venous thromboembolism
Journal
International journal of hematologic oncology
ISSN: 2045-1393
Titre abrégé: Int J Hematol Oncol
Pays: England
ID NLM: 101600758
Informations de publication
Date de publication:
04 Sep 2020
04 Sep 2020
Historique:
entrez:
5
10
2020
pubmed:
6
10
2020
medline:
6
10
2020
Statut:
epublish
Résumé
There are limited data describing incidence of symptomatic venous thromboembolism (VTE) in adolescent and young adult (AYA) acute lymphoblastic leukemia (ALL) patients receiving peg-asparaginase. Single-institution retrospective analysis of 44 AYA ALL patients treated with peg-asparaginase. Rates of VTE and proposed risk factors were assessed. 18 patients (41%) had a symptomatic VTE following peg-asparaginase. The cumulative incidence rate was 25% (95% CI: 13-38%) within 30 days of the initial dose. Personal history of thrombosis was statistically significantly associated with an increased risk of VTE with HR of 2.73 (95% CI: 1.40-5.33, p = 0.003) after adjusting for gender. These data indicate a high rate of VTE in the AYA ALL population following treatment with peg-asparaginase.
Identifiants
pubmed: 33014332
doi: 10.2217/ijh-2020-0009
pmc: PMC7521187
doi:
Types de publication
Journal Article
Langues
eng
Pagination
IJH28Informations de copyright
© 2020 Bhavana Bhatnagar.
Déclaration de conflit d'intérêts
Financial & competing interests disclosure The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties. No writing assistance was utilized in the production of this manuscript.
Références
Semin Thromb Hemost. 2011 Apr;37(3):193-8
pubmed: 21455853
Am J Pediatr Hematol Oncol. 1988 Fall;10(3):191-5
pubmed: 3177809
Blood. 2006 Oct 1;108(7):2216-22
pubmed: 16804111
Eur J Haematol. 1992 Aug;49(2):63-6
pubmed: 1397242
J Thromb Haemost. 2020 Feb;18(2):278-284
pubmed: 31999063
Leuk Lymphoma. 2011 Dec;52(12):2237-53
pubmed: 21827361
J Clin Oncol. 2005 Oct 1;23(28):7161-7
pubmed: 16192600
Leuk Lymphoma. 2020 Mar;61(3):614-622
pubmed: 31680584
Thromb Res. 2019 Dec;184:92-98
pubmed: 31715544
Blood. 2003 Apr 1;101(7):2529-33
pubmed: 12517808
J Clin Oncol. 2019 Jul 1;37(19):1638-1646
pubmed: 30978155
Blood. 2007 May 15;109(10):4164-7
pubmed: 17264295
BMC Pediatr. 2017 May 10;17(1):122
pubmed: 28486976
N Engl J Med. 2004 Jun 17;350(25):2558-63
pubmed: 15201412
Leukemia. 1999 Mar;13(3):335-42
pubmed: 10086723
Clin Adv Hematol Oncol. 2009 Sep;7(9):600-6
pubmed: 20020672
J Clin Oncol. 2013 Mar 20;31(9):1202-10
pubmed: 23358966
J Pediatr. 2011 Jul;159(1):133-7
pubmed: 21353248
Cancer. 2003 Jan 15;97(2):508-16
pubmed: 12518376
Thromb Haemost. 2013 Apr;109(4):633-42
pubmed: 23364346
Am J Hematol. 2018 Oct;93(10):1254-1266
pubmed: 30058716
Arch Intern Med. 1998 Mar 23;158(6):585-93
pubmed: 9521222
Am J Hematol. 2012 May;87(5):472-8
pubmed: 22388572
Cancer. 2013 Jan 1;119(1):90-8
pubmed: 22744771
Blood. 2019 Apr 4;133(14):1548-1559
pubmed: 30658992
Thromb Haemost. 2015 Feb;113(2):247-61
pubmed: 25338526
Br J Haematol. 2011 Feb;152(4):452-9
pubmed: 21210774
Blood. 2016 Apr 28;127(17):2101-12
pubmed: 26888258
Leukemia. 2015 Mar;29(3):526-34
pubmed: 25079173
Cancer. 2004 Dec 15;101(12):2788-801
pubmed: 15481055
Blood. 2018 May 31;131(22):2475-2484
pubmed: 29661787